BidaskClub upgraded shares of DexCom (NASDAQ:DXCM) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

A number of other research firms have also issued reports on DXCM. Barclays reiterated an equal weight rating and issued a $60.00 target price (down previously from $76.00) on shares of DexCom in a research note on Thursday, September 28th. Citigroup lowered DexCom from an outperform rating to a market perform rating in a research note on Thursday, September 28th. Zacks Investment Research upgraded DexCom from a sell rating to a hold rating in a research note on Monday, August 14th. Leerink Swann reiterated a buy rating and issued a $57.00 target price (down previously from $85.00) on shares of DexCom in a research note on Friday, September 29th. Finally, Piper Jaffray Companies reiterated an overweight rating and issued a $78.00 target price (down previously from $87.00) on shares of DexCom in a research note on Wednesday, August 16th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $71.36.

DexCom (DXCM) traded down $1.19 during mid-day trading on Tuesday, hitting $57.04. The stock had a trading volume of 1,365,832 shares, compared to its average volume of 1,655,871. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom has a fifty-two week low of $42.62 and a fifty-two week high of $88.80.

In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $69.81, for a total transaction of $101,224.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total value of $73,280.70. Following the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at approximately $2,915,496.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,955 shares of company stock valued at $2,583,643. 1.70% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in DXCM. Advisor Group Inc. lifted its holdings in DexCom by 104.9% during the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares during the last quarter. Zions Bancorporation lifted its holdings in DexCom by 36,222.2% during the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after buying an additional 3,260 shares during the last quarter. IFP Advisors Inc lifted its holdings in DexCom by 30.5% during the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after buying an additional 568 shares during the last quarter. Toronto Dominion Bank lifted its holdings in DexCom by 251.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after buying an additional 2,608 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in DexCom by 9.2% during the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after buying an additional 250 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “BidaskClub Upgrades DexCom (DXCM) to Strong-Buy” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/bidaskclub-upgrades-dexcom-dxcm-to-strong-buy/1768142.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with Analyst Ratings Network's FREE daily email newsletter.